Scientists discover why ozempic may not work for some people
Scientists have identified genetic variants that may make some people less responsive to GLP-1 drugs used to treat Type 2 diabetes. Roughly 10% of the population carries these variants, which appear …
Scientists have identified genetic variants that may make some people less responsive to GLP-1 drugs used to treat Type 2 diabetes. Roughly 10% of the
Read Full Story at ScienceDaily →Why This Matters
This discovery could fundamentally reshape how Type 2 diabetes is treated, explaining why some patients face frustrating plateaus despite adhering to GLP-1 therapies. Beyond immediate clinical implications, it underscores the growing need for precision medicine in chronic disease management—a shift that could reduce trial-and-error prescribing and improve long-term outcomes.
Background Context
GLP-1 drugs like semaglutide (sold as Ozempic and Wegovy) have transformed diabetes and obesity care since their approval, but their efficacy has always varied unpredictably. Early research focused on lifestyle and metabolic factors, but genetic resistance to these drugs remained a blind spot until now. The study's 10% estimate aligns with growing evidence that pharmacogenomics plays a larger role in medication response than previously assumed.
What Happens Next
Pharmaceutical companies may now prioritize genetic screening in clinical trials to identify non-responders before prescribing, while regulators might push for biomarker labeling on GLP-1 drug packaging. For patients, this could mean faster access to alternative therapies like SGLT2 inhibitors or combination treatments, though such shifts may take years to integrate into standard care.
Bigger Picture
This finding fits a broader trend where genetic insights are unlocking personalized approaches to conditions once treated with one-size-fits-all drugs. As genetic testing becomes cheaper and more accessible, expect similar discoveries across other high-profile therapies, potentially accelerating the decline of blockbuster drug models in favor of targeted treatments.
